<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gabrielle Fröberg</style></author><author><style face="normal" font="default" size="100%">Florian P Maurer</style></author><author><style face="normal" font="default" size="100%">Erja Chryssanthou</style></author><author><style face="normal" font="default" size="100%">Louise Fernström</style></author><author><style face="normal" font="default" size="100%">Hanaa Benmansour</style></author><author><style face="normal" font="default" size="100%">Samira Boarbi</style></author><author><style face="normal" font="default" size="100%">Anne Torunn Mengshoel</style></author><author><style face="normal" font="default" size="100%">Peter Michael Keller</style></author><author><style face="normal" font="default" size="100%">Miguel Viveiros</style></author><author><style face="normal" font="default" size="100%">Diana Machado</style></author><author><style face="normal" font="default" size="100%">Margaret M Fitzgibbon</style></author><author><style face="normal" font="default" size="100%">Simone Mok</style></author><author><style face="normal" font="default" size="100%">Jim Werngren</style></author><author><style face="normal" font="default" size="100%">Daniela Maria Cirillo</style></author><author><style face="normal" font="default" size="100%">Fernando Alcaide</style></author><author><style face="normal" font="default" size="100%">Hanne-Leena Hyyryläinen</style></author><author><style face="normal" font="default" size="100%">Alexandra Aubry</style></author><author><style face="normal" font="default" size="100%">Sönke Andres</style></author><author><style face="normal" font="default" size="100%">Nadarajan, Darshaalini</style></author><author><style face="normal" font="default" size="100%">Erik Svensson</style></author><author><style face="normal" font="default" size="100%">John Turnidge</style></author><author><style face="normal" font="default" size="100%">Christian G Giske</style></author><author><style face="normal" font="default" size="100%">Gunnar Kahlmeter</style></author><author><style face="normal" font="default" size="100%">Emmanuelle Cambau</style></author><author><style face="normal" font="default" size="100%">Jakko van Ingen</style></author><author><style face="normal" font="default" size="100%">Thomas Schön</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">EUCAST AMST and ESCMYC study groups</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.</style></title><secondary-title><style face="normal" font="default" size="100%">Clin Microbiol Infect</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Feb 20</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;b&gt;OBJECTIVE: &lt;/b&gt;For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC) distributions of wild-type isolates have not been systematically evaluated despite their importance for establishing antimicrobial susceptibility testing (AST) breakpoints.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;METHODS: &lt;/b&gt;We gathered MIC distributions for drugs used against the Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI and RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined by EUCAST methodology including quality control (QC) strains.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;RESULTS: &lt;/b&gt;The clarithromycin ECOFF was 16 mg/L for M.&amp;nbsp;avium (n&amp;nbsp;=&amp;nbsp;1271) whereas TECOFFs were 8 mg/L for M.&amp;nbsp;intracellulare (n&amp;nbsp;=&amp;nbsp;415) and 1 mg/L for MAB (n&amp;nbsp;=&amp;nbsp;1014) confirmed by analysing MAB subspecies without inducible macrolide resistance (n&amp;nbsp;=&amp;nbsp;235). For amikacin, the ECOFFs were 64 mg/L for MAC and MAB. For moxifloxacin, the WT spanned &amp;gt;8 mg/L for both MAC and MAB. For linezolid, the ECOFF and TECOFF were 64 mg/L for M.&amp;nbsp;avium and M.&amp;nbsp;intracellulare, respectively. Current CLSI breakpoints for amikacin (16 mg/L), moxifloxacin (1 mg/L) and linezolid (8 mg/L) divided the corresponding WT distributions. For QC M.&amp;nbsp;avium and M.&amp;nbsp;peregrinum, ≥95% of MIC values were well within recommended QC ranges.&lt;/p&gt;

&lt;p&gt;&lt;b&gt;CONCLUSION: &lt;/b&gt;As a first step towards clinical breakpoints for NTM, (T)ECOFFs were defined for several antimicrobials against MAC and MAB. Broad wild-type MIC distributions indicate a need for further method refinement which is now under development within the EUCAST subcommittee for anti-mycobacterial drug susceptibility testing. In addition, we showed that several CLSI NTM breakpoints are not consistent in relation to the (T)ECOFFs.&lt;/p&gt;
</style></abstract></record></records></xml>